Pim-1 at the tumour microenvironment interface: context-specific mechanisms, evidence boundaries and therapeutic opportunities

Pim-1 has been implicated in oncogenic stress adaptation and selected tumour microenvironment interactions, raising interest in PIM-directed treatment. However, the evidence for a broad microenvironmental role remains uneven. Many reported effects derive from pan-PIM or non-exclusive inhibitors, other PIM family members or non-malignant models. Here, we evaluate Pim-1 biology at the tumour–microenvironment interface according to isoform attribution, intervention profile, cellular source, model system and endpoint directness. Pim-1-specific evidence is strongest for myeloid-derived suppressor cell metabolism, tumour-cell control of CCL2-dependent macrophage recruitment, hypoxia-inducible factor phosphorylation and CXCR4-dependent trafficking. Context-specific genetic evidence also supports roles in prostate stromal activation and murine myelofibrosis. By contrast, broad claims about immune remodelling, senescence-associated secretory control, solid-tumour fibrosis and several combination effects remain supported mainly by PIM-family pharmacology or indirect extrapolation. Clinical-stage PIM inhibitors remain pharmacologically heterogeneous, with limited single-agent activity, no validated predictive biomarker and no demonstration of isoform-specific target engagement linked to clinical benefit. We therefore propose a context-to-intervention framework in which disease state and cellular compartment identify the relevant PIM function. That function informs modality choice, while compartment-resolved target engagement links pharmacology to outcome. This framework provides a basis for distinguishing settings that justify selective Pim-1 targeting from those favouring family-wide inhibition or the use of PIM biology as a biomarker and combination rationale.

Authors

Institutions

Publication Details

Journal
Molecular Cancer
Published
2026-11-21
DOI
https://doi.org/10.1186/s12943-026-02833-0
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pim-1 at the tumour microenvironment interface: context-specific mechanisms, evidence boundaries and therapeutic opportunities

Weimin Li, Dandan Liang, Silu Hu, Ting Bao et al.
Molecular Cancer
Immune cells in cancer
article

Pim-1 at the tumour microenvironment interface: context-specific mechanisms, evidence boundaries and therapeutic opportunities

Weimin Li, Dandan Liang, Silu Hu, Ting Bao, Jie Tang, Ruiyao Luo
article en

Abstract

Pim-1 has been implicated in oncogenic stress adaptation and selected tumour microenvironment interactions, raising interest in PIM-directed treatment. However, the evidence for a broad microenvironmental role remains uneven. Many reported effects derive from pan-PIM or non-exclusive inhibitors, other PIM family members or non-malignant models. Here, we evaluate Pim-1 biology at the tumour–microenvironment interface according to isoform attribution, intervention profile, cellular source, model system and endpoint directness. Pim-1-specific evidence is strongest for myeloid-derived suppressor cell metabolism, tumour-cell control of CCL2-dependent macrophage recruitment, hypoxia-inducible factor phosphorylation and CXCR4-dependent trafficking. Context-specific genetic evidence also supports roles in prostate stromal activation and murine myelofibrosis. By contrast, broad claims about immune remodelling, senescence-associated secretory control, solid-tumour fibrosis and several combination effects remain supported mainly by PIM-family pharmacology or indirect extrapolation. Clinical-stage PIM inhibitors remain pharmacologically heterogeneous, with limited single-agent activity, no validated predictive biomarker and no demonstration of isoform-specific target engagement linked to clinical benefit. We therefore propose a context-to-intervention framework in which disease state and cellular compartment identify the relevant PIM function. That function informs modality choice, while compartment-resolved target engagement links pharmacology to outcome. This framework provides a basis for distinguishing settings that justify selective Pim-1 targeting from those favouring family-wide inhibition or the use of PIM biology as a biomarker and combination rationale.

Molecular Cancer
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Sichuan University (CN), West China Hospital of Sichuan University (CN), Institute of Optics and Electronics, Chinese Academy of Sciences (CN)
National Science and Technology Major Project, Fundamental Research Funds for the Central Universities, West China Hospital, Sichuan University
Good health and well-being
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon